TORONTO, ONTARIO -- (MARKET WIRE) -- January 29, 2007 -- OccuLogix, Inc. (NASDAQ: OCCX) (TSX: OC) today announced that it has obtained Investigational Device Exemption clearance from the U.S. Food and Drug Administration ("FDA") to commence its pivotal (phase III) study of the RHEO™ procedure to treat the Dry form of Age-Related Macular Degeneration ("Dry AMD").
